VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DNTHDianthus Therapeutics, Inc.
$83.98$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksDNTHBalance Sheet

Dianthus Therapeutics, Inc. (DNTH) Balance Sheet

10Y historyFree accessUpdated daily

Total debt is minimal at about $1.2M and the D/E ratio is near zero, but cash of $55.7M against quarterly operating outflows near $50M suggests liquidity may be thin despite a current ratio of 30.02.

Income StatementBalance SheetCash FlowRatios

DNTH Balance Sheet

Annual statement

DNTH Balance Sheet

Dianthus Therapeutics, Inc. (DNTH) balance sheet — 10-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets856.04M409.44M280.9M177.45M82.03M180.69M151.53M149.84M145.32M52.5M10.83M
Cash & Short-Term Investments837.78M404.3M275.24M173.72M75.49M176.93M148.84M145.73M142.57M51.57M4.54M
Cash Only55.69M51.09M22.79M132.32M15.37M131.65M58.15M65.07M58.34M51.57M4.54M
Short-Term Investments782.1M353.21M252.45M41.39M60.13M45.28M90.68M80.66M84.22M00
Accounts Receivable582K102K807K478K5.64M000006.25M
Days Sales Outstanding67.8218.2947.2461.74320.69------
Inventory00000000000
Days Inventory Outstanding-----------
Other Current Assets169K5.04M355K504K53K3.77M2.69M4.11M2.75M936K41K
Total Non-Current Assets420.21M121.48M93.1M1.95M1.08M9.24M10.09M11.67M11.99M1.96M508K
Property, Plant & Equipment1.9M1.63M1.75M800K956K7.46M8.31M9.89M3.07M1.74M508K
Fixed Asset Turnover1.61x1.25x3.57x3.53x6.71x0.20x-----
Goodwill00000000000
Intangible Assets00000000000
Long-Term Investments933.68M110.14M81.73M001.78M1.78M1.78M8.92M218K0
Other Non-Current Assets12.27M9.72M9.63M1.15M121K00004K0
Total Assets1.28B530.92M374.01M179.41M83.11M189.93M161.62M161.51M157.31M54.46M11.34M
Asset Turnover0.00x0.00x0.02x0.02x0.08x0.01x-----
Asset Growth %692.76%41.95%108.47%115.86%-56.24%17.52%0.07%2.67%188.84%380.19%-
Total Current Liabilities28.52M30.73M18.45M9.63M8.22M10.86M11.43M14.12M10.42M4.14M2.3M
Accounts Payable5.5M9.72M4.58M2.61M1.17M3.04M3.76M2.81M3.49M167K1.67M
Days Payables Outstanding32.28K-----693.83556.911.46K162.11101.41K
Short-Term Debt00000000000
Deferred Revenue (Current)5.79M1.19M479K100K100K000000
Other Current Liabilities09.52M5.15M5.36M2.08M4.48M4.56M8.06M4.4M2.65M127K
Current Ratio30.02x13.32x15.22x18.42x9.97x16.63x13.26x10.62x13.95x12.68x4.71x
Quick Ratio30.02x13.32x15.22x18.42x9.97x16.63x13.26x10.62x13.95x12.68x4.71x
Cash Conversion Cycle-32.21K----------
Total Non-Current Liabilities6.31M6.79M3.08M904K1.23M6.4M6.28M6.21M1.25M00
Long-Term Debt01.02M000000000
Capital Lease Obligations1.77M01.17M168K438K000000
Deferred Tax Liabilities00000000000
Other Non-Current Liabilities000006.4M6.28M6.21M1.25M00
Total Liabilities34.82M37.52M21.53M10.54M9.45M17.26M17.71M20.32M11.66M4.14M2.3M
Total Debt1.21M1.39M1.49M585K788K000000
Net Debt-54.48M-49.7M-21.3M-131.74M-14.58M-131.65M-58.15M-65.07M-58.34M-51.57M-4.54M
Debt / Equity0.00x0.00x0.00x0.00x0.01x------
Debt / EBITDA-0.01x----------
Net Debt / EBITDA0.23x----------
Interest Coverage-------19.90x----56.86x
Total Equity1.24B493.4M352.48M168.87M73.66M172.67M143.91M141.19M145.65M50.32M9.04M
Equity Growth %719.44%39.98%108.73%129.27%-57.34%19.99%1.92%-3.06%189.44%456.53%-
Book Value per Share21.6513.0510.5832.7719.6650.2852.4261.0369.9522.764.09
Total Shareholders' Equity1.24B493.4M352.48M168.87M73.66M172.67M143.91M141.19M145.65M50.32M9.04M
Common Stock56K43K31K15K059K49K39K33K6K3K
Retained Earnings-474.42M-336.73M-174.39M-89.42M-45.87M-325.57M-254.43M-179.5M-102.73M-45.21M-9.72M
Treasury Stock00000000000
Accumulated OCI-6.28M489K106K47K-161K-30K-23K8K-8K-382K-6K
Minority Interest00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Cash runway shortfall and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Base Expanding Through Financing Events

Based on reported figures, DNTH's total assets rose from $354.2M in 2024Q3 to $1.3B in 2026Q3, while equity climbed to $1.2B, suggesting the balance sheet has grown mainly through capital raises rather than operating earnings.

The jump in assets alongside a retained deficit that widened to -$474.4M points to external funding, not internally generated value, as the driver of growth. The 2026Q1 cash peak of $627.7M followed by a drop to $55.7M by 2026Q3 implies heavy deployment into clinical operations within a few quarters. Investors should monitor whether the asset base reflects durable pipeline value or merely the cash that is being consumed.

Cash Buffer Thins Against Quarterly Burn

As reported in the balance sheet, DNTH held $55.7M in cash at 2026Q3 against a current ratio of 30.02, a liquidity profile that looks comfortable on paper but may be misleading given the scale of operating outflows.

The very high current ratio reflects a large short-term asset base relative to minimal current liabilities of roughly $34.8M total liabilities, rather than operational strength. With quarterly operating burn near $50M, cash on hand may cover only about one quarter of spending. This suggests the liquidity buffer is thin and that a near-term financing event may be required to sustain Phase 2 programs.

Minimal Debt Leaves Equity Funding Dominant

According to recent SEC filings, DNTH carried only about $1.2M of total debt at 2026Q3, with a D/E ratio near zero, indicating the company's capital structure relies almost entirely on equity rather than borrowing.

Negligible debt removes near-term refinancing risk and covenant pressure, which is a relative strength for a pre-revenue biotech. However, the absence of leverage also means the capital structure has no cushion beyond equity issuance, so dilution becomes the primary funding lever. Investors should view the low D/E as a reflection of the company's financing path rather than conservative management.

Deferred Revenue Shrinks Toward Negligible Levels

Based on reported figures, DNTH's deferred revenue fell from $7.8M in 2026Q1 to $7.0M in 2026Q3 after sitting near $740K in 2024Q3, offering little evidence of a contracted revenue backlog ahead.

The deferred revenue balance appears to be tied to legacy collaboration arrangements rather than product sales, and its recent stability does not indicate a growing forward commitment. With TTM revenue near $2.0M and declining, the forward revenue signal is weak. This suggests forward visibility depends on the pipeline reaching clinical milestones rather than on existing customer contracts.

Net Income Flattered by Non-Operating Items

As reported in the income statement, DNTH's 2025Q4 net income of $97.9M against an operating loss of -$69.5M suggests a large non-operating gain that may make the equity and retained earnings picture look better than core operations justify.

A positive net result alongside a deep operating loss implies the headline balance sheet strength may be partly driven by one-time or non-cash items rather than clinical progress. Because retained earnings still sit at -$474.4M, the accumulated deficit remains large and the underlying burn is unchanged. Investors should reconcile the equity base against the underlying operating loss before treating asset growth as evidence of durable value.

DNTH — Frequently Asked Questions

Quick answers to the most common questions about buying DNTH stock.

What are the total assets of Dianthus Therapeutics, Inc. (DNTH)?

As of 2025, Dianthus Therapeutics, Inc. (DNTH) had total assets of $530.9M including $409.4M in current assets.

How much debt does Dianthus Therapeutics, Inc. (DNTH) have?

Dianthus Therapeutics, Inc. (DNTH) carries total debt of $1.4M, offset by $404.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Dianthus Therapeutics, Inc.?

Dianthus Therapeutics, Inc. (DNTH) has total shareholders' equity (book value) of $493.4M ($13.05 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Dianthus Therapeutics, Inc.'s current ratio and liquidity?

Dianthus Therapeutics, Inc. (DNTH) reported a current ratio of 13.32x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.